Chris Shanahan

Chris Shanahan serves as the Vice President of Sales at Verastem Oncology, focusing on the launch of AVMAPKI FAKZYNJA CO-PACK, the first treatment for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer. Prior to this role, Chris held the position of Senior Area Business Director at PharmaEssentia, where responsibilities included co-leading the sales team and launching BESREMi for Polycythemia Vera. As Vice President of Sales at Epizyme, Chris oversaw US sales and commercial training, facilitating the launch of TAZVERIK for two FDA-approved indications. Previous roles also include Vice President of Sales at Takeda Oncology, managing sales teams across various oncology units, and Division Manager at Genentech, where Chris built a new oncology sales team and launched the cancer immunotherapy TECENTRIQ. Chris Shanahan holds a Bachelor of Science in Marketing from Boston College and attended Wilbraham & Monson Academy.